[ 3 ] Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh？et disease: a randomized, placebo-controlled, double-blind study[J]. Arch Dermatol, 1999, 135(5): 529-532.
[6]
[ 4 ] D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-4085.
[7]
[ 5 ] Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still’s disease to thalidomide[J]. Lancet, 1998, 352(9127): 544-545.
[8]
[ 6 ] Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506[J]. Transplantation, 1991, 52(5): 908-910.
[9]
[ 7 ] Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells[J]. Life Sci, 1994, 55(2): 77-92.
[10]
[ 8 ] Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity[J]. Science, 2010, 327(5971):1345-1350.
Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh？et’s syndrome. A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 1998, 128(6): 443-450.
